Oaktree Acquisition Corp. III Life Sciences has officially extended its deadline to complete a business combination, a move that could significantly influence its strategic direction and investor confidence. The blank check company, known for its focus on life sciences, is now set to finalize a deal by November 25, 2026, after shareholders approved an amendment to its articles of association during an extraordinary general meeting.
The extension was made possible by a vote held on October 23, 2026, where shareholders approved the amendment to extend the termination date from October 25, 2026, to November 25, 2026. This decision allows Oaktree to pursue potential business combinations without the pressure of an imminent deadline. Furthermore, the amendment permits Oaktree to extend the termination date on a monthly basis for up to seven additional months, should the sponsor request it.
Background
Oaktree Acquisition Corp. III Life Sciences, classified under the SIC code 6770 for Blank Checks, is a special purpose acquisition company (SPAC) listed on the Nasdaq under the tickers OACC, OACCU, and OACCW. The company focuses on identifying and acquiring businesses in the life sciences sector, leveraging the expertise of its management team and sponsors.
In its recent filings, Oaktree has been active in navigating the complexities of SPAC regulations and market conditions. The company has undergone several significant events, including a recent issuance of shares and amendments to its governing documents.
What the Filing Says
According to the SEC filing dated October 26, 2026, Oaktree issued 4,798,758 Class A ordinary shares to Oaktree Acquisition Holdings III LS, LLC, as part of a conversion process. This issuance was not registered under the Securities Act of 1933, relying on the exemption from registration provided by Section 3(a)(9).
Additionally, the filing details that the extraordinary general meeting, referred to as the Extension Meeting, was attended by shareholders representing approximately 76.3% of the voting power. The results showed overwhelming support for the extension amendment proposal, with 17,956,072 votes in favor compared to 802,517 against.
Impact
This extension could have significant implications for Oaktree's stakeholders, particularly its shareholders and potential acquisition targets. By extending the deadline, Oaktree may enhance its chances of identifying a suitable business combination, which is crucial for the long-term success of the SPAC model. The decision to allow for further extensions without additional shareholder votes may also streamline future processes, making it easier for Oaktree to adapt to changing market conditions.
What's Next
The filing does not specify what happens next, but the company is now focused on identifying potential business combinations before the new termination date. Investors and market analysts will be closely monitoring Oaktree's progress in the coming weeks as it seeks to finalize a deal that aligns with its strategic vision.